NCI has selected Exact Sciences Corp.’s testing laboratory in Phoenix, AZ to participate in the ComboMATCH clinical trials, an NCI-funded precision medicine initiative. As a ComboMATCH-designated lab, Exact Sciences will use its new OncoExTra test to analyze tumor tissue and paired normal blood samples from patient participants and uncover the specific abnormalities in a patient’s tumor that may be most effective to treat.
NCI officials were notably absent from the annual meeting of the Association of American Cancer Institutes and the Cancer Center Administrators Forum in Washington, DC, due to the government shutdown that started on Oct. 1.
